Granules Pharmaceuticals Inc.

Form 483 issued August 21, 2019 · Chantilly, Virginia

Inspection
Aug 7 – Aug 21, 2019
Investigator
Craig D. Zagata
Observations
2
Pages
3
FEI number
3011585184

In short: On August 21, 2019, FDA issued a Form 483 with 2 observations to Granules Pharmaceuticals Inc. in Chantilly, Virginia (FEI 3011585184) after an inspection that ran Aug 7 – Aug 21, 2019. The investigator was Craig D. Zagata. Most observations concern materials; the most-cited regulation is 21 CFR 211.80 (general requirements).

At a glance

2 of 2 observations on this 483 concern materials.

Materials2

Most cited: 21 CFR 211.80 (2×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Incoming components are not stored under quarantine until they have been tested or examined…

  2. 02

    Written procedures are not followed for the storage of components, drug…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Granules Pharmaceuticals Inc.?

FDA listed 2 observations on this Form 483, mostly about materials. The most-cited regulation is 21 CFR 211.80 (general requirements). The opening words of each observation are shown on this page.

Who inspected Granules Pharmaceuticals Inc.?

Craig D. Zagata is named on this Form 483, for the inspection of Aug 7 – Aug 21, 2019. Each investigator has a profile showing what they cite most.

When was Granules Pharmaceuticals Inc. inspected by FDA?

The inspection ran Aug 7 – Aug 21, 2019, and the Form 483 is dated August 21, 2019.

How do I get the full Form 483 for Granules Pharmaceuticals Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free